Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

Design Therapeutics, a biotechnology company focused on developing treatments for degenerative genetic disorders, announced that CEO João Siffert and COO Sean Jeffries will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 11:20 a.m. ET. The event will be available via live webcast on the company's investor site, with an archive accessible for 30 days post-event. Design Therapeutics utilizes its GeneTAC™ platform to treat conditions like Friedreich ataxia and myotonic dystrophy type-1.

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the SVB Leerink 11^th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 11:20 a.m. ET.

A live webcast will be available in the investor section of the company's website at www.designtx.com. The webcast will be archived for 30 days following the presentation.

About Design Therapeutics
Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.

Contact:
Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

FAQ

When is the fireside chat for Design Therapeutics at the SVB Leerink Global Healthcare Conference?

The fireside chat for Design Therapeutics will take place on February 17, 2022, at 11:20 a.m. ET.

How can I watch the Design Therapeutics fireside chat?

You can watch the Design Therapeutics fireside chat via a live webcast on their investor section at www.designtx.com.

What is the focus of Design Therapeutics' research?

Design Therapeutics focuses on developing therapies for degenerative genetic disorders, particularly using their GeneTAC™ platform.

What are some diseases targeted by Design Therapeutics?

Design Therapeutics targets diseases like Friedreich ataxia and myotonic dystrophy type-1.

What is the main feature of Design Therapeutics' GeneTAC™ platform?

The GeneTAC™ platform by Design Therapeutics allows for precise modulation of disease-causing gene expression.